Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 60% Improvement Relative Risk Assad et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 291 patients in Iraq (June - September 2020) Lower mortality with HCQ (p=0.0019) Assad, H., Current Issues in Pharmacy and Medica.., doi:10.2478/cipms-2022-0020 Favors HCQ Favors control
Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19
Assad, H., Current Issues in Pharmacy and Medical Sciences, doi:10.2478/cipms-2022-0020
Assad, Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19, , H., Current Issues in Pharmacy and Medical Sciences, doi:10.2478/cipms-2022-0020
Oct 2022   Source   PDF  
  All Studies   Meta
Retrospective 346 hospitalized patients in Iraq, showing lower mortality with HCQ in unadjusted results. HCQ results are only provided within the 93% of patients treated with enoxaparin. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details; confounding by time possible, propensity to use HCQ changed significantly during the study period.
risk of death, 59.7% lower, RR 0.40, p = 0.002, treatment 9 of 72 (12.5%), control 68 of 219 (31.1%), NNT 5.4, enoxaparin+HCQ vs. enoxaparin.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Assad et al., 21 Oct 2022, retrospective, Iraq, peer-reviewed, 1 author, study period June 2020 - September 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: DOI: 10.2478/cipms-2022-0020 Curr. Issues Pharm. Med. Sci., Vol. 35, No. 3, Pages 106-110 Current Issues in Pharmacy and Medical Sciences Formerly ANNALES UNIVERSITATIS MARIAE CURIE-SKLODOWSKA, SECTIO DDD, PHARMACIA journal homepage: Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19 Hayder Assad Department of Clinical Pharmacy, Faculty of Pharmacy, University of Kufa, Najaf, Iraq ARTICLE INFO Received 08 October 2021 Accepted 10 June 2022 Keywords: COVID-19, hospitalized patients, medications, mortality rate. ABSTRACT There are many treatment modalities for COVID-19 – with varied outcome. Therefore, authors designed this study to assess prescribing patterns and the clinical outcome for hospitalized patients with severe and critical COVID-19 so as to determine the most effective approach. Authors conducted a retrospective observational study on 346 adult patients with either severe or critical COVID-19, who were admitted to public hospitals in Al-Najaf city, Iraq from June to September 2020. Patients' information, medications and outcomes were collected from their medical records in the registered office of the hospital. A total of 346 patients were enrolled, with a majority of patients being adults above 35 years old and male (70.2%). Most patients (81%) received corticosteroid as dexamethasone, and about 45% of all patients were given convalescent plasma therapy, while a few patients were prescribed antiviral favipiravir (23%) and lopinavir/ritonavir (19%). As supportive care medications, anticoagulant such as enoxaparin was administered to most of the patients (93%) and more than half of all patients received the broad-spectrum antibiotic, meropenem. The majority of the patients recovered and were discharged alive (66%), however, the inhospital mortality rate was 26%. Interestingly, patients treated with enoxaparin alone or in combination with hydroxychloroquine were associated with better outcome. The prescribing pattern of COVID-19 specific medications and supportive care is aligned with guideline recommendations and associated with a beneficial therapeutic outcome.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop